


Prostate Cancer Research Review™



Making Education Easy

Issue 66 - 2023

In this issue:

- > Fifteen-year prostate cancer outcomes after monitoring, surgery, or radiotherapy
- > Androgen receptor proteolysis targeting chimeras
- > Nomogram of outcomes for PSMA-PET-based salvage radiotherapy
- > Abiraterone + enzalutamide for metastatic prostate cancer
- > Intraoperative fluorescence imaging of PSMA-positive prostate cancer
- > PSA level at salvage radiotherapy and risk of death
- > MRI and biomarkers for diagnosis in high genetic prostate cancer risk
- > Prior local therapy and response to androgen receptor axis-targeted therapy in mCRPC
- > Outcomes of germline *BRCA2* mutation carriers
- > Preoperative endogenous total testosterone and prostate cancer progression

Abbreviations used in this issue:

ADT = androgen deprivation therapy; BMI = body mass index; CI = confidence interval; Gy = Gray; HR = hazard ratio; ISUP = International Society of Urological Pathology; LHRH = luteinising hormone-releasing hormone; mCRPC = metastatic castration-resistant prostate cancer; MRI = magnetic resonance imaging; OS = overall survival; PET = positron-emission tomography; PI-RADS = Prostate Imaging-Reporting and Data System; PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; RARP = robot-assisted radical prostatectomy; RCT = randomised controlled trial; TRUS = transrectal ultrasound scan.

Welcome to Issue 66 of Prostate Cancer Research Review.

In a UK study comparing 15-year outcomes of active monitoring, prostatectomy, or radiotherapy in men with prostate cancer, prostate cancer-specific mortality was low regardless of the treatment assigned. Analysis of a large international database found that among men with pT2-4N0 or NXM0 prostate cancer, initiating salvage radiation therapy above a PSA of 0.25 ng/mL was associated with increased all-cause mortality risk. Meanwhile, preoperative endogenous total testosterone level has been identified as a predictor of prostate cancer progression.

I hope you find the research in this issue useful to you in your practice and I look forward to your comments and feedback.

Kind Regards,

Associate Professor Niall Corcoran
niall.corcoran@researchreview.com.au

Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer

Authors: Hamdy FC et al.

Summary: This randomised controlled trial (RCT) compared outcomes in 1643 men assigned to active monitoring (n = 545), prostatectomy (n = 553), or radiotherapy (n = 545) after a median follow-up of 15 years in 98% of participants. Prostate cancer-related death occurred in 45 (2.7%) patients, including 17 (3.1%) active-monitoring, 12 (2.2%) prostatectomy, and 16 (2.9%) radiotherapy recipients. Metastases developed in 51 (9.4%) active monitoring recipients, 26 (4.7%) prostatectomy recipients, and 27 (5.0%) radiotherapy recipients. Long-term ADT was used in 69 (12.7%), 40 (7.2%), and 42 (7.7%), while 141 (25.9%), 58 (10.5%), and 60 (11.0%), respectively, experienced clinical progression. At the end of follow-up, 133 (24.4%) men receiving active monitoring remained alive with no prostate cancer treatment. There was no difference in cancer-specific mortality associated with baseline PSA level, tumour stage or grade, or risk-stratification score. There were no treatment complications identified over a 10-year analysis.

Comment: This updated ProtecT publication reports on the 15-year outcomes in men aged between 50 and 69 diagnosed with clinically localised disease based on an elevated PSA, randomised to surgery, radiation, or active monitoring. Similar to the 10-year data, active monitoring was associated with an increased risk of metastatic events, but this did not translate into a difference in overall survival (OS). The event rate in the cohort overall was very low (6.3% for metastasis and 2.7% for prostate cancer-related deaths), which is likely due to the preponderance of lower risk cases included in the study, which may limit the power to detect differences in patients with higher-risk disease. That said, 20-30% of patients had intermediate-/high-risk disease at diagnosis, and there was likely significant under-grading of tumours at diagnosis based upon limited core TRUS biopsies without MRI. It is also important to note that the control arm was not 'no treatment', as 60% of men progressed to active radical treatment at some stage, although often many years down the track.


Reference: *N Engl J Med.* 2023;388(17):1547-1558

[Abstract](#)

Claim CPD/CME points [Click here](#) for more info.

Kindly supported by





Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

Authors: Hung C-L et al.

Summary: This study assessed the use of Proteolysis Targeting Chimeras (PROTAC) to induce degradation of both full-length androgen receptor (AR) and ligand-binding domain truncated AR variants. *In vitro*, PROTAC degraded both proteins via the ubiquitin-proteasome system, causing impaired AR transactivation on target gene expression, and reduced cell proliferation along with apoptosis activation. PROTAC also inhibited enzalutamide-resistant growth of castration-resistant prostate cancer cells. In a castration-, enzalutamide-resistant xenograft model, one PROTAC compound had good oral bioavailability and strong antitumor efficacy.

Comment: AR signalling is important in driving prostate cancer progression, and therapies that target this by suppressing androgen synthesis (e.g., LHRH agonists/antagonists, abiraterone) or receptor binding/nuclear translocation/DNA binding (e.g., enzalutamide, darolutamide etc.) are the backbone of treatment of advanced disease. Overexpression of AR or a number of constitutively active splice variants have been associated with resistance to AR targeting agents, prompting investigators to develop novel therapeutic strategies to combat this. This interesting study describes a novel proteolysis targeting chimera that uses the N-terminal domain to AR as a bait for the native receptor and a ubiquitin ligase-binding moiety to target it for degradation. The authors demonstrate activity with oral dosing in an animal model of castration- and enzalutamide-resistance, however, demonstrating target protein specificity will be key to clinical translation.

Reference: *EBioMedicine* 2023;90:104500

[Abstract](#)

Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer

Authors: Zamboglou C et al.

Summary: This retrospective cohort study sought to develop and validate a nomogram for prediction of freedom from biochemical failure after PSMA-PET-targeted salvage radiotherapy based on 1029 patients with prostate cancer divided into a training dataset (n = 708), an internal validation dataset (n = 271), and external outlier validation dataset (n = 50). Over a median follow-up of 32 months, 437 (42.5%) patients had local recurrences and 313 (30.4%) patients had nodal recurrences. Multivariate analysis suggested that freedom from biochemical failure was associated with baseline PSA level (HR 1.80; 95% CI 1.41-2.31), surgery specimen ISUP grade 5 versus grade 1/2 (HR 2.39; 95% CI 1.63-3.50), pT3b/pT4 stage versus pT2 stage (HR 1.91; 95% CI 1.39-2.67), R0 versus R1/R2/Rx surgical margins (HR 0.60; 95% CI 0.48-0.78), ADT (HR 0.49; 95% CI 0.37-0.65), salvage radiotherapy dose >70 versus ≤66 Gy (HR 0.44; 95% CI 0.29-0.67), and nodal recurrence observed with PSMA-PET (HR 1.42; 95% CI 1.09-1.85). Mean nomogram concordance index for freedom from biochemical failure was 0.72 in the internal validation dataset and 0.67 with the external outlier validation dataset.

Comment: PSMA-PET is now the go-to investigation in patients with biochemically recurrent disease post prostatectomy considering salvage pelvic radiation. However, how the results impact on rates of success of salvage therapy in patients with a negative scan or pelvic only recurrence is unclear. This large retrospective multicentre study investigated factors associated with freedom from biochemical recurrence in patients undergoing salvage radiotherapy in whom distant disease was excluded by PSMA-PET. Interestingly, although the presence of lymph node disease was independently associated with a higher risk of failure, it was not the strongest factor in the model, with pre-radiotherapy PSA levels, tumour grade and stage dominating. That said, salvage treatment may have been influenced by the PET findings (ADT use, pelvic side wall radiation etc.), so the real value may be underestimated.

Reference: *JAMA Netw Open* 2023;6(5):e2314748

[Abstract](#)

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: Final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Authors: Attard G et al.

Summary: This pooled analysis of two multinational, randomised, controlled, open-label, phase III STAMPEDE platform protocol trials examined long-term outcomes and the effect of combining enzalutamide with abiraterone and ADT on survival in 1003 patients with metastatic prostate cancer receiving standard of care (SOC; n = 502) or SOC plus abiraterone (n = 501) in an abiraterone trial and 916 patients receiving SOC (n = 454) or SOC plus abiraterone and enzalutamide (n = 462) in an abiraterone plus enzalutamide trial. Over a median follow-up of 96 months in the abiraterone trial and 72 months in the abiraterone plus enzalutamide trial, median OS was 76.6 months (95% CI 67.8-86.9) in abiraterone versus 45.7 months (95% CI 41.6-52.0) in SOC recipients (HR 0.62; 95% CI 0.53-0.73; p < 0.0001), and 73.1 months (95% CI 61.9-81.3) in abiraterone plus enzalutamide versus 51.8 months (95% CI 45.3-59.0) in SOC recipients (HR 0.65; 95% CI 0.55-0.77; p < 0.0001). There was no difference in treatment effect between the trials (interaction HR 1.05; 95% CI 0.83-1.32) or between-trial heterogeneity. Over the initial 5 years of treatment, grade 3-5 toxic effects were greater with abiraterone plus SOC versus SOC (54% vs 38%) and abiraterone plus enzalutamide plus SOC versus SOC (68% vs 45%). The most common cause of death due to adverse events was cardiac related.

Comment: Triplet therapy, combining ADT plus chemotherapy plus a novel androgen receptor signalling inhibitor upfront in patients with metastatic hormone-sensitive prostate cancer is currently flavour of the month, although the additional benefit is still being debated. So, what about combining two novel androgen signalling inhibitors with proposed independent mechanisms of action with ADT with or without docetaxel? This timely report analysed data from two RCTs from within the STAMPEDE arm, which investigated the benefit of SOC versus SOC plus abiraterone, as well as SOC versus SOC plus abiraterone and enzalutamide. Consistent with previous reports, adding abiraterone to SOC improved OS, however the addition of enzalutamide did not appear to result in any additional therapeutic benefit (with all the caveats of inter-trial comparisons!). Toxic effects were higher for SOC plus abiraterone, and higher still for the abiraterone plus enzalutamide combination.

Reference: *Lancet Oncol.* 2023;24(5):443-456

[Abstract](#)

First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: A single-arm, phase 2a, feasibility trial


Authors: Stibbe JA et al.

Summary: This Dutch single-arm, phase IIa feasibility trial examined targeted real-time imaging during robot-assisted radical prostatectomy (RARP) using the PSMA-targeted fluorescent tracer OTL78 in 18 patients (median age 69 years, median PSA 15 ng/mL) with prostate cancer. In 16 (89%) patients, RARP was accompanied by extended pelvic lymph node dissection. There were three serious adverse events in one (6%) patient considered unrelated to OTL78 or intraoperative fluorescence imaging; infected lymphocele, urosepsis, and intraperitoneal haemorrhage. Dose-normalised maximum serum concentration (C_{max}/dose) was 84.1 ng/mL/mg using a 0.03 mg/kg dose and 79.6 ng/mL/mg using a 0.06 mg/kg dose, half-lives were 5.1 hours and 4.7 hours, while volumes of distribution were 22.9 L and 19.5 L, and clearances were 3.1 L/h and 3.0 L/h.

Comment: Being able to visualise cancer directly during radical prostatectomy would be expected to improve neurovascular bundle preservation and urethral length, while at the same time maximising surgical clearance with negative margins. This first-in-man study from the Netherlands examined the efficacy of three different dosing regimens of a novel fluorescent agent consisting of a high affinity PSMA-targeting ligand conjugated to a near-infrared dye, with fluorescence detected intraoperatively with Visionsense near-infrared imaging system (Medtronic) and visualised with the TilePro function of the Da Vinci Surgical System. Sensitivity for the visual detection of tumour intra-operatively was pretty good compared with *ex-vivo* back-table imaging (up to 65%) and microscopic assessment (up to 89%), although it did vary with tumour grade, volume and PSMA staining intensity. We now need demonstration that its use can impact oncological and functional outcomes.

Reference: *Lancet Oncol.* 2023;24(5):457-467

[Abstract](#)



THERE'S SURVIVING and there's Living*

NOW REGISTERED for mHSPC¹

*In nmCRPC: NUBEQA® + ADT significantly improved OS vs ADT alone (HR 0.69, 95% CI 0.53-0.88; P=0.003 [secondary endpoint]); significantly improved MFS vs ADT alone (40.4 vs 18.4 months; HR 0.41, 95% CI 0.34-0.50; P<0.001 [primary endpoint]). Patient QOL was maintained throughout the duration of treatment; frequency of AEs and discontinuations were comparable to ADT alone.^{1,3} In mHSPC: NUBEQA® + ADT/docetaxel delivered a 32.5% reduction in risk of death vs ADT/docetaxel (HR 0.68, 95% CI 0.57-0.80; P<0.001 [primary endpoint]); frequency of AEs and discontinuations were comparable to ADT/docetaxel alone.^{1,4}

NUBEQA® (darolutamide) for mHSPC and nmCRPC

- ✓ The only ARI to deliver **>30% reduction in risk of death** across mHSPC and nmCRPC:^{1,3-6}
In mHSPC 32.5% reduction in risk of death vs ADT/docetaxel: HR 0.68, 95% CI 0.57-0.80, P<0.001, primary endpoint.^{1,4}
In nmCRPC 31% reduction in risk of death vs placebo/ADT: HR 0.69, 95% CI 0.53-0.88, P=0.003, secondary endpoint.^{1,3}
- ✓ Delivers **more time: >2x longer without cancer progressing** in mHSPC and nmCRPC:^{1,4,6}
In mHSPC >2x longer time to progression to CRPC vs ADT/docetaxel: HR 0.36, 95% CI 0.30-0.42, P<0.001, secondary endpoint.^{1,4}
In nmCRPC >2x longer metastasis-free survival vs placebo/ADT: HR 0.41, 95% CI 0.34-0.50, P<0.001, primary endpoint.^{1,6}

mHSPC Patient Access Program



Scan here or visit www.nubeqaPAP.com.au to find out more about interim access to NUBEQA® for eligible patients with mHSPC



ADT, androgen deprivation therapy; AE, adverse event; ARI, androgen receptor inhibitor; CI, confidence interval; CRPC, castration resistant prostate cancer; HR, hazard ratio; MFS, metastasis-free survival; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, non-metastatic castration resistant prostate cancer; OS, overall survival; QOL, quality of life.

PBS Information: This product is not listed on the PBS for mHSPC. This product is listed on the PBS for nmCRPC. Authority Required (immediate/real-time assessment by Services Australia). Refer to PBS schedule for more information www.pbs.gov.au

Please review Product Information before prescribing. Full Product Information available at <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2020-PI-01276-1> or upon request from Bayer Australia Ltd. ABN 22 000 138 714. 875 Pacific Highway, Pymble NSW 2073.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.


MINIMUM PRODUCT INFORMATION NUBEQA® (darolutamide)

INDICATIONS: NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. **CONTRAINDICATIONS:** Hypersensitivity to darolutamide or excipients in tablet, women who are or may become pregnant. **PRECAUTIONS:** Cardiovascular events (the safety of darolutamide has not been characterised in patients with recent (within 6 months) cardiovascular events), hepatic impairment, renal impairment. The safety and efficacy in children and adolescents (< 18 years) have not been established. Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA. Patients should be monitored for signs and symptoms of ischemic heart disease. Optimise management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. Seizure occurred in patients receiving NUBEQA. **INTERACTIONS WITH OTHER MEDICINES:** Darolutamide is a substrate of CYP3A4, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Darolutamide is an inhibitor of BCRP and Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3 and a weak inducer of CYP3A4. In vitro data indicate darolutamide administration may inhibit OAT3, MATE1, MATE2K and intestinal MRP2. Darolutamide did not inhibit the transporters, BSEP, OAT1, OCTs, OATP2B1 and NTCP at clinically relevant concentrations. Please refer to the full Product Information for more information. **ADVERSE EFFECTS:** The most frequently observed adverse drug reaction (≥ 10%, very common) in patients with nmCRPC receiving NUBEQA is fatigue. The most frequently observed adverse drug reaction (>10%) in patients with mHSPC receiving NUBEQA in combination with docetaxel were constipation (23%), decreased appetite (19%), rash (19%) and hypertension (14%). Drug-induced liver injury with increases in ALT and AST has been reported in patients treated with NUBEQA in clinical trials. **Laboratory test abnormalities** include neutrophil count decrease, bilirubin increase and AST increase in nmCRPC patients. Laboratory test abnormalities include anaemia, white blood cell and neutrophil count decrease, ALT and AST increase, hyperglycaemia and hypocalcaemia in patients with mHSPC. Please refer to full Prescribing Information for a complete list of adverse effects and laboratory test abnormalities. **DOSAGE AND ADMINISTRATION:** 600 mg (two film-coated tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. The tablets should be taken whole with food. Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) analogue concurrently or should have had bilateral orchiectomy. In case of toxicity or an intolerable adverse reaction, dosing should be withheld or reduced. For more information see full Prescribing Information. **DATE OF PREPARATION:** March 2023, based on PI dated Mar-2023.

References: 1. NUBEQA® (darolutamide) Approved Product Information. 2. Fizazi K et al. N Engl J Med 2019;380(13):1235-1246. 3. Fizazi K et al. N Engl J Med 2020;383(11):1040-1049. 4. Smith MR et al. N Engl J Med 2022;386(12):1132-1142. 5. Smith MR et al. Eur Urol 2021;79(1):150-158. 6. Sternberg CN et al. N Engl J Med 2020;382(23):2197-2206.

NUBEQA® is a registered trademark of Bayer Group, Germany. Bayer Australia Limited. ABN 22 000 138 714. 875 Pacific Highway, Pymble NSW 2073. NUB145 | April 2023 | PP-NUB-AU-0273-1





Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death

Authors: Tilki D et al.

Summary: This analysis of a multinational database of 25,551 patients with pT2-4N0 or NXM0 prostate cancer, examined whether there is a PSA level after PSA failure above which initiating salvage radiotherapy is associated with increased all-cause mortality. Over a median follow-up of 6.0 years, salvage radiotherapy at a PSA level >0.25 ng/mL had a higher all-cause mortality risk (adjusted HR 1.49; 95% CI 1.11-2.00; p = 0.008) versus PSA ≤0.25 mg/mL. This elevated risk was observed at all PSA thresholds in 0.05 ng/mL increments up to 0.50 ng/mL, but not at PSA levels below 0.25 ng/mL.

Comment: The optimal PSA threshold at which to initiate salvage therapy for biochemically recurrent prostate cancer is unknown. Given that PSMA-PET imaging is more likely to be positive at higher PSA levels, the authors suggest there is a concern that patients' salvage treatment may be delayed in some men as the PSA rises to a point at which imaging is more likely to be informative, which may adversely affect treatment outcomes. In this context the authors performed a retrospective review of the impact of incremental increases in PSA level at which salvage radiation was instituted on all-cause mortality, finding that salvage radiotherapy started at a PSA level >0.25 ng/ml was associated with worse outcomes compared to when it was commenced below this threshold. Interesting data but needs to be interpreted with caution given the number of potential confounders (performance status, co-morbidities etc.) that may impact OS as well as the PSA threshold at which salvage radiotherapy is instituted.

Reference: *J Clin Oncol.* 2023;41(13):2428-2435

[Abstract](#)

Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk

Authors: Cussenot O et al.

Summary: This study examined different scenarios for the management of early diagnosis in 322 men at high genetic risk for prostate cancer, using blood and urinary molecular biomarkers with multiparametric MRI (mpMRI). An mpMRI PI-RADS score ≥3 had higher sensitivity than a PI-RADS score ≥4 for detection of prostate cancer (82% vs 61%) and for the detection of ISUP grade >1 lesions (96% vs 80%). An mpMRI PI-RADS score ≥3 was also better than a PSA level of ≥3 ng/mL for both sensitivity (96% vs 91%) and specificity (53% vs 8%) of detecting clinically significant prostate cancer. With negative mpMRI results, the most useful indicators of decision to biopsy were urinary markers and PSA density ≥0.10 ng/mL/mL.

Comment: What is the optimal test to screen for early prostate cancer in patients at high genetic risk of the disease? This study compared the sensitivity and specificity of a number of different tests (PSA level, PSA density, prostate health index, urine Prostate Cancer antigen 3 score, urine levels of the gene fusion of androgen-regulated transmembrane serine protease [TMPRSS2] and the erythroblast transformation specific [ETS] transcription factor [T2:ERG] score, and prostate MRI) for the detection of clinically significant prostate cancer in men with a significant family history of prostate cancer or carriers of a known predisposing germline variant undergoing a 12-core TRUS biopsy. Overall MRI (PI-RADS >3) was the best performing test on which to decide to biopsy regardless of PSA level, although performance improved when PSA and PSA density were also included. Important information, and certainly justifies the lower PSA threshold for accessing Medicare Benefits Schedule rebateable MRIs in patients with a family history.

Reference: *BJU Int.* 2023;131(6):745-754

[Abstract](#)

Effect of prior local therapy on response to first-line androgen receptor axis targeted therapy in metastatic castrate-resistant prostate cancer: A secondary analysis of the COU-AA-302 trial


Authors: Roy S et al.

Summary: This exploratory analysis of the multicentre double-blinded, randomised controlled, phase III COU-AA-302 trial of abiraterone plus prednisone or placebo plus prednisone in 1053 docetaxel-naive mCRPC patients with no to mild symptoms assessed whether prior prostate-directed local therapy (n = 669; 64%) altered response to first-line systemic therapy and survival. There was no heterogeneity of time-dependent treatment effects of abiraterone on radiographic progression-free survival with prior local therapy (HR 0.36; 95% CI 0.27-0.49) at ≤6 months or > 6 months (HR 0.64; 95% CI 0.49-0.83) or without prior local therapy (HR 0.37; 95% CI 0.26-0.55 at ≤6 months; HR 0.72; 95% CI 0.50-1.03 at >6 months). There was also no heterogeneity of abiraterone effects on OS with prior local therapy (HR 0.88; 95% CI 0.71-1.10) at ≤36 months or at >36 months (HR 0.76; 95% CI 0.52-1.11) or without prior local therapy (HR 0.78; 95% CI 0.60-1.01 at ≤36 months; HR 0.55; 95% CI 0.30-0.99 at >36 months). Overall, prior local therapy was associated with an improvement in OS (average HR 0.72; 95% CI 0.59-0.89).

Comment: An older medical oncology colleague used to say that patients with metastatic disease were easier to manage when the prostate was out, presumably due to the reduction in complications related to local progression. Another suggested advantage is that local therapy may remove a major potential source of treatment resistant cell populations, and thereby prolong the efficacy of systemic treatments. This analysis from the COU-AA-302 trial, which demonstrated an improvement in OS in men with chemotherapy-naive mCRPC randomised to receive abiraterone plus prednisone or placebo plus prednisone, shows that although prior local therapy (radical prostatectomy, radiotherapy, or radical prostatectomy plus radiotherapy) did not affect the efficacy of abiraterone, it was associated with an observed increase in OS. Would assume this reflects the different disease trajectories of synchronous versus metachronous disease, rather than a true treatment benefit.

Reference: *Eur Urol.* 2023;83(6):571-579

[Abstract](#)

Complete Care for Prostate Cancer and Urological Conditions		Australian Prostate Centre 
<p style="text-align: center;">Urological Services</p> <ul style="list-style-type: none"> ▪ Prostate cancer incl. full survivorship services. ▪ Uro-oncology. ▪ General + functional urology. ▪ Genomic testing. ▪ Prostate biopsy (transperineal in-rooms). ▪ Flexible cystoscopy (same day). ▪ Continence clinic incl. urodynamics & bladder Botox (males & females). ▪ Hormone therapy survivorship clinic. ▪ Pelvic pain clinic. 	<p style="text-align: center;">Complete Care Outpatient Clinic</p> <ul style="list-style-type: none"> ▪ Not-for-profit outpatient urology service for patients with or without health insurance. ▪ Rapid access for all referrals (<1 week urgent, 2-3 weeks routine). ▪ Low fees and bulk billing available. ▪ Onsite procedures incl. flexible cystoscopy and prostate biopsy. 	<p style="text-align: center;">Multidisciplinary Team</p> <ul style="list-style-type: none"> ▪ Urologists. ▪ Radiation oncologists. ▪ Medical oncologists. ▪ Endocrinologists. ▪ Pain physician. ▪ Urology nurses and nurse practitioners. ▪ Pelvic floor physiotherapists. ▪ Exercise physiologists (with on-site gym). ▪ Psychologists.
<p>Level 8, 14-20 Blackwood Street, North Melbourne VIC 3051 T: 03 8373 7600 F: 03 9328 5803 info@apcr.org.au www.australianprostatecentre.org.au</p>		




ANZUP
ANZ Society of Urologists

ANZUP ANNUAL SCIENTIFIC MEETING

9-11 JULY 2023
 'BOUNCING BACK'

RACP MyCPD participants can claim **the time spent reading and evaluating research reviews** as CPD in the online **MyCPD program**.

Please contact MyCPD@raccp.edu.au for any assistance.



Impact of concurrent tumour events on the prostate cancer outcomes of germline *BRCA2* mutation carriers

Authors: Lozano R et al.

Summary: This study examined the role of somatic genomic alterations and histology subtypes in 73 germline *BRCA2* mutation carriers and non-carriers. Somatic *BRCA2-RB1* co-deletion (41% vs 12%; $p < 0.001$) and *MYC* amplification (53.4% vs 18.8%; $p < 0.001$) were enriched in patients with germline *BRCA2* compared to sporadic tumours. Median cause-specific survival from diagnosis of cancer was 9.1 in germline *BRCA2* carriers versus 17.6 years in non-carriers (HR 2.12; $p = 0.002$), median cause-specific survival in germline *BRCA2* carriers was 11.3 in the absence of *BRCA2-RB1* deletion and 13.4 years without *MYC* amplification, while the median cause-specific survival of non-carriers was 8 years with *BRCA2-RB1* deletion and 2.6 years with *MYC* amplification.

Comment: It is clear from the IMPACT study that patients with germline mutations in *BRCA2* have a higher incidence of prostate cancer diagnosis, younger age of diagnosis as well as more adverse pathological features compared to non-carriers. Multiple studies also show that germline mutations in *BRCA2* are associated with reduced metastasis free- and castration resistance free-survival, as well as increased cancer-specific mortality. This retrospective case control study investigated the impact of germline mutations on the acquisition of high-risk somatic alterations in the tumour and subsequent outcomes. They find that patients with germline *BRCA2* mutations more commonly had intra-tumoural *RB1* co-deletion and *MYC* amplification, which were associated with further significant reductions in survival outcomes. This compounding effect of high-risk genomic features is increasingly recognised in early prostate cancer and may be important in clinical risk stratification in the near future.

Reference: *Eur J Cancer* 2023;185:105-118

[Abstract](#)

Preoperative endogenous total testosterone predicts prostate cancer progression: Results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease

Authors: Porcaro AB et al.

Summary: This study examined the role of endogenous total testosterone (ETT) level (≤ 350 vs > 350 ng/dL) as a predictor of prostate cancer progression in 580 patients treated with RARP for clinically localised disease. Preoperative ETT ≤ 350 ng/dL was observed in 173 (29.8%) patients and disease progression occurred in 101 (17.1%) patients. Patients who progressed were more likely to have PSA > 10 ng/mL, along with unfavourable tumour grade (ISUP 4-5) and stage pT3b at final pathology, but were less likely to have ETT ≤ 350 ng/mL. Multivariate analysis suggested that ETT ≤ 350 ng/mL had a protective effect on tumour progression (HR 0.57; $p = 0.013$). Patients with ETT levels ≤ 350 ng/mL were less likely to have ISUP 4-5 tumours at either biopsy (OR 0.46; $p = 0.028$) or final pathology (OR 0.45; $p = 0.032$).

Comment: The relationship between circulating androgen levels and prostate cancer incidence and prognosis is complex, but there is certainly evidence that tumours that develop in a low androgen signalling environment (for instance a bulky primary with a low PSA) are associated with adverse pathological features and poorer outcomes. Adding to the complexity is this Italian series, which finds that high levels of total testosterone prior to RARP were associated with higher tumour grade, whereas a low pre-operative total testosterone was an independent protective factor against tumour progression. Patients with low testosterone were more likely to be overweight/obese, so may well be just a surrogate of the established impact of BMI on prostate cancer outcomes.

Reference: *Int Urol Nephrol.* 2023;55(5):1139-1148

[Abstract](#)



Prostate Cancer Research Review™

Independent commentary by Associate Professor Niall Corcoran.

Associate Professor Niall Corcoran is a urological surgeon at the Royal Melbourne and Frankston Hospitals, and a principal research fellow in the Department of Surgery, University of Melbourne. He is also the Research and Education Lead for GU oncology for the Victorian Comprehensive Cancer Centre.

23rd ASIA-PACIFIC PROSTATE CANCER CONFERENCE
APCC23
TOGETHER IN DISCOVERY & CARE
Caliris Convention Centre | Cairns, Australia
18 – 20 August, 2023

REGISTRATION OPEN

Get your own copy of PROSTATE CANCER RESEARCH REVIEW

Become one of Research Review's
50,000 members

SIMPLY CLICK

I am a Health Professional

to send us an e-mail and we'll do the rest

Australian Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Research Reviews are prepared with an independent commentary from relevant specialists. To become a reviewer please email geoff@researchreview.com.au.

Research Review Australia Pty Ltd is an independent Australian publisher. Research Review receives funding from a variety of sources including Government depts., health product companies, insurers and other organisations with an interest in health. Journal content is created independently of sponsor companies with assistance from leading local specialists. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for Australian health professionals.

